You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for Patent: 11,096,913

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,096,913 protect, and when does it expire?

Patent 11,096,913 protects TIROSINT-SOL and is included in one NDA.

This patent has thirteen patent family members in eleven countries.

Summary for Patent: 11,096,913

Title:	High-stability packaged solutions of T4 thyroid hormone
Abstract:	The invention relates to highly stable alcohol-free, water-glycerol solutions of T4 thyroid hormone, with a reduced amount of T3 impurity, packaged via specific container arrangements. The containers are multi-barrier ones, in which a number of layers of specific materials separate the solution from contact with the external environment.
Inventor(s):	Fossati; Tiziano (Moltrasio, IT), Bellorini; Lorenzo (Comerio, IT), Pizzutti; Marco (Sorengo, CH)
Assignee:	ALTERGON SA (Lugano, CH)
Application Number:	16/697,924
Patent Claim Types: see list of patent claims	Composition; Formulation;

Drugs Protected by US Patent 11,096,913

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ibsa	TIROSINT-SOL	levothyroxine sodium	SOLUTION;ORAL	206977-001	Dec 15, 2016		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Ibsa	TIROSINT-SOL	levothyroxine sodium	SOLUTION;ORAL	206977-002	Dec 15, 2016		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Ibsa	TIROSINT-SOL	levothyroxine sodium	SOLUTION;ORAL	206977-013	Jan 13, 2021		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Ibsa	TIROSINT-SOL	levothyroxine sodium	SOLUTION;ORAL	206977-014	Jan 13, 2021		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Ibsa	TIROSINT-SOL	levothyroxine sodium	SOLUTION;ORAL	206977-003	Dec 15, 2016		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Ibsa	TIROSINT-SOL	levothyroxine sodium	SOLUTION;ORAL	206977-015	Jan 13, 2021		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 11,096,913

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	16194294	Oct 18, 2016

International Family Members for US Patent 11,096,913

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	3037808	⤷ Sign Up
China	109789213	⤷ Sign Up
Denmark	3528847	⤷ Sign Up
European Patent Office	3311844	⤷ Sign Up
European Patent Office	3528847	⤷ Sign Up
Spain	2824787	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.